These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

499 related items for PubMed ID: 24473492

  • 1. Systemic preexposure prophylaxis for HIV: translating clinical data to clinical practice.
    Li J, Dufrene SL, Okulicz JF.
    Ann Pharmacother; 2014 Apr; 48(4):507-18. PubMed ID: 24473492
    [Abstract] [Full Text] [Related]

  • 2. Pregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trial.
    Mugo NR, Hong T, Celum C, Donnell D, Bukusi EA, John-Stewart G, Wangisi J, Were E, Heffron R, Matthews LT, Morrison S, Ngure K, Baeten JM, Partners PrEP Study Team.
    JAMA; 2014 Apr; 312(4):362-71. PubMed ID: 25038355
    [Abstract] [Full Text] [Related]

  • 3. Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings.
    Myers GM, Mayer KH.
    AIDS Patient Care STDS; 2011 Feb; 25(2):63-71. PubMed ID: 21284497
    [Abstract] [Full Text] [Related]

  • 4. Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial.
    Celum C, Morrow RA, Donnell D, Hong T, Hendrix CW, Thomas KK, Fife KH, Nakku-Joloba E, Mujugira A, Baeten JM, Partners PrEP Study Team.
    Ann Intern Med; 2014 Jul 01; 161(1):11-9. PubMed ID: 24979446
    [Abstract] [Full Text] [Related]

  • 5. What primary care providers need to know about preexposure prophylaxis for HIV prevention: a narrative review.
    Krakower D, Mayer KH.
    Ann Intern Med; 2012 Oct 02; 157(7):490-7. PubMed ID: 22821365
    [Abstract] [Full Text] [Related]

  • 6. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness.
    Paltiel AD, Freedberg KA, Scott CA, Schackman BR, Losina E, Wang B, Seage GR, Sloan CE, Sax PE, Walensky RP.
    Clin Infect Dis; 2009 Mar 15; 48(6):806-15. PubMed ID: 19193111
    [Abstract] [Full Text] [Related]

  • 7. Emtricitabine/tenofovir disoproxil fumarate: a review of its use in HIV-1 pre-exposure prophylaxis.
    Plosker GL.
    Drugs; 2013 Mar 15; 73(3):279-91. PubMed ID: 23444256
    [Abstract] [Full Text] [Related]

  • 8. Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals.
    Okwundu CI, Uthman OA, Okoromah CA.
    Cochrane Database Syst Rev; 2012 Jul 11; 2012(7):CD007189. PubMed ID: 22786505
    [Abstract] [Full Text] [Related]

  • 9. Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial.
    Mugwanya KK, Wyatt C, Celum C, Donnell D, Mugo NR, Tappero J, Kiarie J, Ronald A, Baeten JM, Partners PrEP Study Team.
    JAMA Intern Med; 2015 Feb 11; 175(2):246-54. PubMed ID: 25531343
    [Abstract] [Full Text] [Related]

  • 10. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
    Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, Tappero JW, Bukusi EA, Cohen CR, Katabira E, Ronald A, Tumwesigye E, Were E, Fife KH, Kiarie J, Farquhar C, John-Stewart G, Kakia A, Odoyo J, Mucunguzi A, Nakku-Joloba E, Twesigye R, Ngure K, Apaka C, Tamooh H, Gabona F, Mujugira A, Panteleeff D, Thomas KK, Kidoguchi L, Krows M, Revall J, Morrison S, Haugen H, Emmanuel-Ogier M, Ondrejcek L, Coombs RW, Frenkel L, Hendrix C, Bumpus NN, Bangsberg D, Haberer JE, Stevens WS, Lingappa JR, Celum C, Partners PrEP Study Team.
    N Engl J Med; 2012 Aug 02; 367(5):399-410. PubMed ID: 22784037
    [Abstract] [Full Text] [Related]

  • 11. Preexposure prophylaxis for the prevention of HIV transmission to women.
    Aaron E, Cohan D.
    AIDS; 2013 Jan 02; 27(1):F1-5. PubMed ID: 22914582
    [Abstract] [Full Text] [Related]

  • 12. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
    Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, Henderson FL, Pathak SR, Soud FA, Chillag KL, Mutanhaurwa R, Chirwa LI, Kasonde M, Abebe D, Buliva E, Gvetadze RJ, Johnson S, Sukalac T, Thomas VT, Hart C, Johnson JA, Malotte CK, Hendrix CW, Brooks JT, TDF2 Study Group.
    N Engl J Med; 2012 Aug 02; 367(5):423-34. PubMed ID: 22784038
    [Abstract] [Full Text] [Related]

  • 13. Study design considerations for evaluating efficacy of systemic preexposure prophylaxis interventions.
    Donnell D, Hughes JP, Wang L, Chen YQ, Fleming TR.
    J Acquir Immune Defic Syndr; 2013 Jul 02; 63 Suppl 2(0 2):S130-4. PubMed ID: 23764624
    [Abstract] [Full Text] [Related]

  • 14. HIV-serodiscordant couples desiring a child: 'treatment as prevention,' preexposure prophylaxis, or medically assisted procreation?
    Mabileau G, Schwarzinger M, Flores J, Patrat C, Luton D, Epelboin S, Mandelbrot L, Matheron S, Yazdanpanah Y.
    Am J Obstet Gynecol; 2015 Sep 02; 213(3):341.e1-12. PubMed ID: 25979615
    [Abstract] [Full Text] [Related]

  • 15. Preexposure chemoprophylaxis for HIV prevention.
    Lee DH, Vielemeyer O.
    N Engl J Med; 2011 Apr 07; 364(14):1372-3; author reply 1374-5. PubMed ID: 21470026
    [No Abstract] [Full Text] [Related]

  • 16. Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence.
    Celum C, Baeten JM.
    Curr Opin Infect Dis; 2012 Feb 07; 25(1):51-7. PubMed ID: 22156901
    [Abstract] [Full Text] [Related]

  • 17. Concentrations of tenofovir and emtricitabine in saliva: implications for preexposure prophylaxis of oral HIV acquisition.
    de Lastours V, Fonsart J, Burlacu R, Gourmel B, Molina JM.
    Antimicrob Agents Chemother; 2011 Oct 07; 55(10):4905-7. PubMed ID: 21788466
    [Abstract] [Full Text] [Related]

  • 18. Preexposure prophylaxis for HIV infection among African women.
    Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, Malahleha M, Owino F, Manongi R, Onyango J, Temu L, Monedi MC, Mak'Oketch P, Makanda M, Reblin I, Makatu SE, Saylor L, Kiernan H, Kirkendale S, Wong C, Grant R, Kashuba A, Nanda K, Mandala J, Fransen K, Deese J, Crucitti T, Mastro TD, Taylor D, FEM-PrEP Study Group.
    N Engl J Med; 2012 Aug 02; 367(5):411-22. PubMed ID: 22784040
    [Abstract] [Full Text] [Related]

  • 19. Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single- or dual-agent preexposure prophylaxis.
    Lehman DA, Baeten JM, McCoy CO, Weis JF, Peterson D, Mbara G, Donnell D, Thomas KK, Hendrix CW, Marzinke MA, Frenkel L, Ndase P, Mugo NR, Celum C, Overbaugh J, Matsen FA, Partners PrEP Study Team.
    J Infect Dis; 2015 Apr 15; 211(8):1211-8. PubMed ID: 25587020
    [Abstract] [Full Text] [Related]

  • 20. Preexposure prophylaxis for HIV prevention: where have we been and where are we going?
    Baeten JM, Haberer JE, Liu AY, Sista N.
    J Acquir Immune Defic Syndr; 2013 Jul 15; 63 Suppl 2(0 2):S122-9. PubMed ID: 23764623
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.